101 results about "Epidermal growth factor" patented technology

The invention relates to the technical field of medical dressings, in particular to a perianal drug dressing of a multi-layer flow guide composite fabric and a preparation method and application of the perianal drug dressing of the multi-layer flow guide composite fabric. The perianal drug dressing is of a four-layer structure, a wet tissue adhesion layer is made of polydopamine modified chitosan / oxidized hyaluronic acid hydrogel, and wet-state adhesion is achieved; the drug sustained-release layer is used for dispersing mesoporous silica loaded with ciprofloxacin hydrochloride / defensin and chitosan microspheres loaded with epidermal growth factors / lonicera japonica into a polycaprolactone fiber membrane to achieve synergistic antibacterial and healing promotion; the directional flow guide layer is of a gradient wettability sandwich structure with a bionic micro-channel, and one-way rapid drainage can be achieved; the high-absorption outer layer is carboxymethyl cellulose / sodium polyacrylate composite sponge, liquid is locked efficiently, the wound surface is kept dry and comfortable, the clinical problem in perianal infection wound treatment can be effectively solved, and the treatment effect and the patient comfort are remarkably improved.

The invention discloses a pseudo-ginseng exosome-like nano vesicle loaded with an epidermal growth factor / application of the pseudo-ginseng exosome-like nano vesicle in wound healing. The research shows that not all exosome-like nano-vesicles from Chinese herbal medicines capable of promoting wound healing have the effect of promoting wound healing, the action mechanism of the pseudo-ginseng exosome-like nano-vesicles in wound healing is further explored, and the research shows that PNVs can promote the proliferation and migration of an epidermal keratinocyte line, so that the PNVs can be used for promoting the healing of the wound. The treatment can be realized by regulating and controlling the activity of immune cells to promote cell proliferation and migration, and the wound healing effect of the EGF-loaded EGF-coated PNVs is remarkably enhanced, so that the EGF-loaded EGF-coated PNVs have a synergistic effect. The invention not only provides a theoretical basis for deeply researching PELNVs, but also provides a new method and a new idea for treating acute wounds.

The invention discloses a composite gel for skin correction and a preparation method thereof. The composite gel is formed by dissolving sodium hyaluronate, epidermal growth factors and a protein stabilizer in a buffer system; the content of the sodium hyaluronate is 1.0-50.0 g / L, the content of the epidermal growth factor is 1000-30000 IU / mL, and the content of the stabilizer is 5.0-100.0 mg / L; the pH value of the buffer system is 6.5-7.5. The preparation method comprises the following steps: S1, dissolving sodium hyaluronate and a stabilizer in a buffer system under a sterile condition, and stirring to obtain gel A; s2, adding epidermal growth factors into the gel A, and stirring to obtain the composite gel. The composite gel disclosed by the invention can activate epithelial fibroblasts, update and reconstruct ECM and maintain the stability of an ECM microenvironment. The composite gel disclosed by the invention integrates the functions of supplementing lost extracellular matrix, increasing the number of cells and promoting synthesis of collagen by a traditional filling material, can solve the skin problems caused by various factors, and achieves the effect of correcting the skin.

The invention relates to an extraction and culture method of urine-derived stem cells, and belongs to the field of cell biology and regenerative medicine. The method comprises the following steps: coating a culture plate with a gelatin solution; collecting clean midstream urine of healthy people and adding antibiotics; centrifugally separating the cell precipitate; washing with a phosphate buffer solution; re-suspending the precipitate by using a urine stem cell complete culture medium for primary culture; and after the cells grow to a certain fusion degree, carrying out passage amplification. The urine stem cell complete medium comprises a basic medium, fetal calf serum, epidermal growth factors, platelet-derived growth factors and basic fibroblast growth factors. By adopting the method disclosed by the invention, the urine-derived stem cells can be efficiently and stably separated from urine, and the obtained cells have high multiplication capacity, good stemness maintaining capacity, multidirectional differentiation potential and immunoregulation function, and can provide an ideal seed cell source for treating diseases such as diabetic erectile dysfunction.

The application provides a culture medium and a culture method of ovarian cancer primary cells. The culture medium comprises an MST1 / 2 kinase inhibitor, sodium pyruvate, forskolin, epidermal growth factor, gastrin, fibroblast growth factor 7, nicotinamide, SB431542, and fetal bovine serum. Compared with the existing culture method, the in-vitro culture using the culture medium of the application has higher amplification efficiency; the culture of the ovarian cancer primary cells using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the ovarian cancer primary cell culture.

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

The application relates to the technical field of medical dressing preparation, and discloses a hemostatic, healing-promoting and antibacterial foam dressing and a preparation method thereof. The method uses sodium alginate and carboxymethyl chitosan as a composite polysaccharide matrix, mixes the two, adds a calcium chloride solution to crosslink a porous gel support, and then carries out freeze-drying to obtain a porous framework; gelatin and polyvinyl alcohol can be further added to enhance the mechanical strength, zeolite particles loaded with silver ions are added to achieve antibacterial performance, epidermal growth factor release microspheres are added to promote healing, and the dressing can be further subjected to heparinization, plasma surface modification, thrombin addition, salt precipitation pore formation and sterilization treatment. The dressing prepared by the method has the functions of synergistic hemostasis, antibiosis and healing promotion, has good biocompatibility and suitable mechanical strength, and has a simple preparation process, and can be used for various wound care.

The invention belongs to the technical field of exosomes, and discloses an exosome preparation method and application, the exosome preparation method comprises the following steps: S1, culturing target cells in an induction medium, and collecting the cells and a culture solution; s2, separating the culture solution to obtain supernate A and cell precipitate; s3, performing chromatographic purification and concentration on the supernate A to obtain the exosome; in the step S1, colchicine is also added in the process of culturing the target cells to synchronize the cell cycle; a polycaprolactone-gelatin composite microcarrier is suspended in the induction culture medium, and nicotinamide, an epidermal growth factor (EGF) and pyruvic acid are contained in the induction culture medium; the method further comprises a step S30 before the step S3, resuspending the cell precipitate obtained in the step S2 with a vesicle protection solution containing trehalose, sucrose and EDTA to obtain a supernatant B, and then combining the supernatant A with the supernatant B. According to the preparation method provided by the invention, the total secretion amount of target cells is large, the intracellular vesicle-exosome precursor can be collected, and the obtained exosome is high in concentration and low in impurity content.

The invention discloses a system for directionally differentiating chicken primordial germ cells into gametes in vitro and a regulation and control method, the system comprises a basic culture medium: based on DMEM / F12, adding 10% of fetal calf serum, 2% of chicken serum, 2 mmol / L of L-glutamine, 1 mmol / L of sodium pyruvate and 5.5 * 10 <-5 > mol / L of beta-mercaptoethanol; the spermatogonium induction culture medium further comprises BMP4, RA and GDNF; the oogonium induction culture medium also comprises BMP15, GDF9 and EGF (Epidermal Growth Factor). According to the system and the regulation and control method, the differentiation efficiency is improved, the culture period is shortened, and the number of cell clusters is remarkably increased.

This invention relates to a skin cell dispersion for autologous treatment of skin wounds. Specifically, this invention provides a skin cell dispersion containing skin cells, epidermal growth factor, and transforming growth factor-β1. The skin cell dispersion of this invention exhibits excellent therapeutic effects on skin wounds.

The present disclosure relates to a composition comprising a peptide having at least 90% sequence homology to a peptide of SEQ ID No. 1 and epidermal growth factor (EGF). It also relates to a process of preparing the composition and its use in treating wounds, including diabetic wound complications.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

The invention provides an application of an epidermal growth factor (EGF) in induction of apoptosis of an upper urinary tract epithelial carcinoma organ (UTUC), and belongs to the technical field of biomedicine. The invention relates to an application of an EGF (Epidermal Growth Factor) or EGFR (Epidermal Growth Factor Receptor) agonist in inducing The EGF induces apoptosis of the upper urinary tract epithelial cancer organoid by activating the STAT1-Caspase 3 pathway and up-regulating the expression level of the EGFR. In view of the fact that the upper urinary tract epithelium carcinoma organoid and the upper urinary tract epithelium carcinoma tissue are highly consistent in form and regulation mechanism, the technical scheme provided by the invention provides a new thought for the medicine for preventing and / or treating the upper urinary tract epithelium carcinoma.

The invention discloses an internal jugular vein semi-permanent catheter with a self-adaptive epidermal growth factor release mechanism, and belongs to the technical field of medical instruments. The catheter comprises a catheter body and a multifunctional medicine release covering film arranged at the telecentric end in a covering mode, the covering film is made of biocompatible polymers, epidermal growth factors (EGF) and antibacterial agents are loaded on the covering film in a gradient mode, and a micro sensor is arranged in the covering film. The sensor is linked with an intelligent feedback system, the drug release rate can be dynamically adjusted according to local physiological conditions, and meanwhile wireless data transmission and remote monitoring are supported. The defects of an existing semi-permanent catheter in the aspects of infection prevention, healing promotion and dynamic adjustment are overcome, targeted drug release, continuous antibiosis, self-adaptive feedback and remote management are achieved, and the long-term implantation requirement is met.

In one aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid, at least one helper lipid, cholesterol, and at least one polymer conjugated lipid. In certain embodiments, the LNP further comprises at least one cargo molecule. In certain embodiments, the LNP comprises an epidermal growth factor (EGFR) targeting domain. In another aspect, the present disclosure provides a method of delivering a cargo to the placenta of a subject. In another aspect, the present disclosure provides a method of treating, preventing, and / or ameliorating a placental disease and / or disorder in a subject. In certain embodiments, the placental disease and / or disorder is pre-eclampsia.

The application belongs to the field of fluorescent probes, and particularly relates to a tumor-targeting photothermal reagent based on fluoro-rhodamine, and a preparation method and application thereof. To solve the problems that most of existing photothermal reagents have difficulty in post-modification due to complex synthesis, poor biological compatibility due to large molecular weight, and lack of tumor targeting of these molecules, and generally need to be made into nanoparticles to enrich to the tumor site by EPR effect, the application develops a tumor-targeting photothermal reagent Tag-880-NHS based on fluoro-rhodamine, which has the characteristics of simple synthesis, good water solubility, good light stability, high photothermal conversion efficiency, and an absorption wavelength located in the NIR region, and can be used for labeling a specific targeting epidermal growth factor monoclonal antibody-panitumumab, and can be used in the fields of tumor imaging and treatment, and has important application value.

The application discloses a kind of modular serum-free cell culture medium and its application, belong to biomedical technology field.The culture medium includes: epidermal growth factor, recombinant insulin, cholesterol-phospholipid nanoparticles, beta-mercaptoethanol, pluronic F-68, glucose / glutamine, trace element mixed solution.The modular serum-free cell culture medium provided by the application can not only meet the large-scale culture of stem cells, but also be used for the industrial production of in vitro diagnostic reagent raw materials such as recombinant antigen, viral vector, recombinant protein and monoclonal antibody, with wide cell adaptability, low production cost, significant economy, stable process, and strict requirements of FDA / EMA for biological products.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.

The present application relates to compositions and methods for treating and preventing fibrosis and other diseases comprising polypeptides derived from MFG-E8, wherein the polypeptides comprise an epidermal growth factor (EGF)-like domain, a C1 domain, and optionally a signal peptide, wherein the polypeptides: (a) lack a functional C2 domain; and / or (b) lack a medin polypeptide or fragment thereof.

The invention discloses a culture medium for in-vitro adherent culture of primary tumor cells and application, and relates to the technical field of tumor cell culture. Comprising a basic culture medium, fetal calf serum FBS with the concentration of 5 ng / mL-15 ng / mL, an epidermal growth factor EGF with the concentration of 1 ng / mL-10 ng / mL, a basic fibroblast growth factor bFGF with the concentration of 0.5 ng / mL-5 ng / mL, an insulin-transferrin-selenium ITS supplement with the final volume concentration of 0.1%-1%, L-glutamine with the final volume concentration of 0.5 mM-2 mM, ascorbic acid with the final volume concentration of 0.1%-0.5% and non-essential amino acid with the final volume concentration of 1%-5%. The kit comprises 10 [mu] g / mL-50 [mu] g / mL of heparin and 1 [mu] g / mL-5 [mu] g / mL of an Rho kinase inhibitor. The culture medium overcomes the defects that in the prior art, when primary tumor cells are subjected to adherent culture, apoptosis or dedifferentiation is prone to occurring, in-vivo tumor characteristics are difficult to simulate, the tumor growth speed is low, the proliferation effect is poor, and the adherent rate is low.

The present invention relates to human monoclonal antibodies that bind to epidermal growth factor-like repeats and discoidin I-like domain 3 (EDIL3) and methods of use thereof.

The present invention relates to the fields of Biotechnology and Medicine. It describes the use of therapeutic compositions comprising a compound that blocks the epidermal growth factor and an antibody that blocks the PD-1 / PD-1 ligand signalling pathway in the treatment of tumours of epithelial origin, particularly those expressing the native form of the human KRAS protein. An increase in survival was observed in patients with cancer of epithelial origin expressing native KRAS treated with said therapeutic compositions.

The present invention provides a primary cell culture medium for culturing primary lung cancer epithelial cells, comprising an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor, at least one additive selected from the group consisting of a B27 additive and an N2 additive, epidermal growth factor, transferrin, gastrin, and a TGFβ type I receptor inhibitor. The present invention also relates to a culture method using the primary cell culture medium and its use in drug efficacy evaluation and screening. The culture method uses the primary cell culture medium to culture primary lung cancer cells on a culture vessel coated with extracellular matrix gel, resulting in rapid proliferation of the primary lung cancer cells. The cell model obtained using the primary cell culture medium and primary cell culture method of the present invention can be used for drug efficacy evaluation and screening.

The invention discloses a skincare stem cell exosome separation and extraction method, and relates to the technical field of biological medicine, the skincare stem cell exosome separation and extraction method comprises the following steps: S1, culture of mixed stem cells: unfreezing urine-derived stem cells and pilose antler stem cells, resuspending in an improved DMEM culture medium, and carrying out mixed culture to prepare a mixed culture solution; epidermal growth factors, cholera toxin, penicillin, streptomycin, transferrin, IL-2 and IL-15 are added into the improved DMEM culture medium; s2, pretreatment of the mixed culture solution: performing centrifugal treatment on the mixed culture solution, and separating to obtain a precipitate and a supernatant, the precipitate being mixed stem cells. The urine-derived stem cells and the pilose antler stem cells are subjected to mixed culture and matched with the improved culture medium containing IL-2, IL-15 and other components, so that the yield and biological activity of the exosome are remarkably improved, high purity and low impurity protein residue of the exosome are achieved by means of a complete purification process of multi-step centrifugation, ultrafiltration concentration and filter membrane filtration, and the yield of the exosome is improved. The skin allergy stimulation risk is effectively reduced.

The application discloses application of a silk fibroin nanoparticle hydrogel in treatment of pressure sore ulcers and relates to the technical field of biochemistry.The core points of the technical solution include the following steps: S1, preparation of a silk fibroin solution;S2, preparation of nanoparticles;S3, production and preparation of milk fat globule epidermal growth factor VIII (MFG-E8) in exosomes;S4, purification of MFG-E8 protein;S5, preparation of silk fibroin nanoparticles coated with MFG-E8;S6, preparation of MFG-E8-silk fibroin nanoparticles crosslinked with NGR peptides; and S7, preparation of a collagen / silk fibroin hydrogel.The silk fibroin nanoparticle hydrogel is a non-invasive treatment method and is more easily accepted by patients in clinical application.In addition, the targeted nanoparticle treatment method for pressure sore sites can significantly improve the treatment effect of patients.

The invention relates to the technical field of protein purification, and provides a method for eukaryotic purification of alpha-syn A53T protein through HEK293 cells. The method comprises the following steps: constructing a recombinant expression plasmid containing an SNCA-A53T mutation target fragment, inserting an affinity tag, transferring into escherichia coli, and performing amplification expression to obtain an endotoxin-free superhelix plasmid for transfection; inoculating HEK293 cells, and adding L-glutamine into the culture medium; the preparation method comprises the following steps: adding endotoxin-free superhelix plasmids and polyethyleneimine into HEK293 cells in sequence, uniformly mixing, standing, adding into the HEK293 cells, and supplementing feed Feed-1, L-glutamine, glucose, epidermal growth factors (EGF) and basic fibroblast growth factors (bFGF); agarose magnetic beads are specifically combined with an affinity tag, and then the magnetic beads are washed and eluted to obtain the purified alpha-syn A53T protein. A supplementary material Feed-1, an epidermal growth factor (EGF) and a basic fibroblast growth factor (bFGF) are introduced in an induced expression stage, so that the expression quantity and the purity of the alpha-syn A53T protein are effectively improved, and the structural stability and the functional integrity of the alpha-syn A53T protein are enhanced.

The present application relates to a culture method and culture medium for reducing the number of epithelial organoids and in vivo tissue differential transcripts, which solves the technical problems of low growth rate and low formation rate of organoids in the prior art. The epithelial organoid culture medium contains basic components and additional components. The basic components contain DMEM / F12 basic medium, penicillin-streptomycin solution, Glutamax additive, recombinant vertebral protein, recombinant cephalopod protein, Y-27632, epidermal growth factor, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021. The additional components contain Wnt-3A, ITS-X additive and hydrocortisone. The present application simultaneously provides a culture method for epithelial organoids. The present application can be used for the culture of epithelial organoids.

The application discloses an epidermal growth factor adding effect prediction method based on growth performance data, relates to the technical field of time series data analysis, and comprises the following steps: collecting target object data and structuring the data, establishing an original data set containing growth performance time series, environmental variables and epidermal growth factor adding dose records; calculating residual errors after preprocessing, performing wavelet decomposition, and combining input features; inputting a double-track learning model to obtain individualized causal effect estimation and dose-time-growth performance prediction mapping, then performing new observation of the target object to establish a correction factor, and outputting a prediction result after compensation. The application solves the technical problem that traditional epidermal growth factor adding effect prediction lacks consideration of dynamic changes in the time dimension and individual differences of different target objects, and cannot meet the precise evaluation and individualized regulation, and achieves the technical effect of accurate and comprehensive prediction of the epidermal growth factor adding effect.

The invention belongs to the technical field of stem cells, and particularly relates to an in-vitro amplification process of umbilical cord mesenchymal stem cells. The in-vitro amplification process of the umbilical cord mesenchymal stem cells comprises the following steps: inoculating the mesenchymal stem cells into a DMEM-containing low-sugar culture medium, adding noricaritin, a recombinant human epidermal growth factor and andrographolide, continuously culturing, and collecting the cells. According to the method, low-dose andrographolide, noricaritin and epidermal growth factors are added into a basic culture medium in stages, synergistic interaction is achieved among the andrographolide, the noricaritin and the epidermal growth factors, cell proliferation is promoted, cell activity is improved, meanwhile, the synergistic pharmacological action is achieved, the active oxygen level is reduced, oxidative damage is inhibited, and a continuously-amplified low-oxidation environment is created for cells; the cell dryness and the long-term passage capability are maintained.